<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01761890</url>
  </required_header>
  <id_info>
    <org_study_id>CML1113</org_study_id>
    <secondary_id>RSO ID 714</secondary_id>
    <nct_id>NCT01761890</nct_id>
  </id_info>
  <brief_title>Front-line Treatment of BCR-ABL+ Chronic Myeloid Leukemia (CML) With Dasatinib</brief_title>
  <acronym>CML1113</acronym>
  <official_title>Front-line Treatment of BCR-ABL+ Chronic Myeloid Leukemia (CML) With Dasatinib. An Observational Multicentric Study.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Gruppo Italiano Malattie EMatologiche dell'Adulto</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Gruppo Italiano Malattie EMatologiche dell'Adulto</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The GIMEMA CML Working Party promotes a multicentric, observational, non company sponsored,
      prospective study of Chronic Myeloid Leukemia (CML) patients treated frontline with
      dasatinib. Patients will be followed for 5 years. This study will help the definition of
      guidelines for the treatment of CML patients in early phases.

      The primary objective of the study is to describe, in the clinical practice, the rate of
      events leading to permanent discontinuation after 2 years of treatment with dasatinib as
      frontline therapy in newly diagnosed CML patients.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The primary objective is to describe, in the clinical practice, the rate of events leading to
      permanent discontinuation after 2 years of treatment with dasatinib as frontline therapy in
      newly diagnosed CML patients. Imatinib mesylate, a protein tyrosine kinase inhibitor (TKI)
      targeting BCR-ABL, has become in the last decade the standard of care for Chronic Myeloid
      Leukaemia (CML) in chronic phase (CP)1-3. Dasatinib is a second generation TKI, effective in
      imatinib-resistant and imatinib-intolerant patients, which demonstrated superior efficacy to
      imatinib in early CP BCR-ABL+ CML patients 4,6,7. Most data on second generation TKIs are
      from company-sponsored studies, generally implemented in selected referral centres. The
      long-term outcome is still unknown. The high rate of study discontinuation observed within
      the phase 3 study may influence the mid-term and the long-term data interpretation6,7. A
      long-term post-marketing surveillance in large independent trial is extremely important to
      confirm the feasibility of a frontline treatment with the second generation TKI dasatinib and
      to evaluate the efficacy in a nationwide experience. Moreover, obtaining a deep molecular
      response is extremely relevant in order to consider TKIs discontinuation. This condition is
      known as &quot;Complete Molecular Response&quot; (CMR) and is further defined according to the
      sensitivity achieved (for the definition see the &quot;Criteria of evaluation&quot; section). As far as
      treatment discontinuation, two experiences have been published so far, aimed at evaluating
      the persistence of the CMR after imatinib discontinuation. The first was a pilot study32
      where 12 patients were included. These 12 patients discontinued imatinib after at least 2
      years of CMR (median duration of negativity, 32 months). Six patients displayed a molecular
      relapse with a detectable BCR-ABL transcript at 1, 2, 3, 4, and 5 months. Imatinib was then
      reintroduced and led to a novel molecular response. Six other patients (50%) still have an
      undetectable level of BCR-ABL transcript after a median follow-up of 18 months (range, 9-24
      months). The results of this pilot trial have been confirmed and extended in a second trial,
      the STIM trial33: 100 patients were enrolled, median follow-up 17 months, 69 patients with at
      least 12 months follow-up: 42 (61%) of these 69 patients relapsed (40 before 6 months, one
      patient at month 7, and one at month 19). At 12 months, the probability of persistent CMR for
      these 69 patients was 41% (95% CI 29-52). All patients who relapsed responded to
      reintroduction of imatinib. An increase of the CMR rate could possibly translate in a higher
      proportion of patients candidate to stopping anti-CML treatment, with higher probability of
      remaining disease-free in the long term. Interestingly, dasatinib was able to induce higher
      36-month cumulative MR4 and MR4.5 rates than imatinib7. The advantages of this possible
      future scenario could be: first, the possibility of treatment discontinuation at least in
      patients with chronic clinical adverse events; second, a potential reduction of the costs of
      TKI treatment (after the introduction of TKI, the costs of CML treatment is increasing year
      by year, with the increasing prevalence of CML patients).

      In summary, 1) Most data on second generation TKIs are from company-sponsored studies; 2) The
      high rate of study discontinuation observed within the phase III study may influence the data
      interpretation; 3) A long-term post-marketing surveillance in large independent trial is
      extremely important to confirm the efficacy in a nationwide experience; 4) The persistence of
      CMR after TKI discontinuation have been described in selected patients with &quot;deep&quot; molecular
      response; 5) A stable CMR is a pre-requisite for treatment discontinuation; 6) A detailed
      description of the kinetic of the molecular response, potentially related to a subsequent
      treatment discontinuation, will be done.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">January 2014</start_date>
  <completion_date type="Anticipated">November 2020</completion_date>
  <primary_completion_date type="Anticipated">March 2018</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Case-Only</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Number of dasatinib permanent discontinuing patients.</measure>
    <time_frame>After 2 years from study entry.</time_frame>
    <description>The cumulative rate of dasatinib permanent discontinuation by 2 years.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Number of dasatinib permanent discontinuing patients.</measure>
    <time_frame>After 5 years from study entry.</time_frame>
    <description>The cumulative rate of dasatinib permanent discontinuation by 5 years.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of confirmed MR4 and MR4.5.</measure>
    <time_frame>After 2 years from study entry.</time_frame>
    <description>The rate of confirmed MR4 and MR4.5 by 24 months.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of confirmed MR4 and MR4.5.</measure>
    <time_frame>After 60 months from study entry.</time_frame>
    <description>The rate of confirmed MR4 and MR4.5 by 60 months.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of stable MR4 and MR4.5 and characteristics.</measure>
    <time_frame>After 60 months from study entry.</time_frame>
    <description>The stability of MR4 and MR4.5.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Complete Cytogenetic Responses (CCgR)</measure>
    <time_frame>After one year from study entry.</time_frame>
    <description>The rate of Complete Cytogenetic Response (CCgR) at 1 year.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Major Molecular Response (MMR).</measure>
    <time_frame>After one year from study entry.</time_frame>
    <description>The rate of Major Molecular Response (MMR) at 1 year.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of days to response (CCgR, MMR, MR4, MR4.5).</measure>
    <time_frame>After 4 years from study entry.</time_frame>
    <description>The median time to response and the overall estimated probability of response (CCgR, MMR, MR4, MR4.5).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of overal surviving patients</measure>
    <time_frame>After five years from study entry.</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of progression-free survival patients.</measure>
    <time_frame>After five years from study entry.</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of failure-free survival patients.</measure>
    <time_frame>After five years from study entry.</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of event-free survival patients.</measure>
    <time_frame>After five years from study entry.</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of responses</measure>
    <time_frame>After 7 years from study entry.</time_frame>
    <description>Overall responses and long-term outcome according to baseline prognostic factors (including: Sokal score34, Euro score35 and EUTOS score36; presence of additional chromosomal abnormalities in Ph+ cells; BCR-ABL transcript type; comorbidity score index).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of responses according to BCR-ABL transcript levels.</measure>
    <time_frame>After 3 and 6 months from study entry.</time_frame>
    <description>Overall responses and long-term outcome according to BCR-ABL transcript levels and CgR at 3 months and at 6 months.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of patients with fasting glucose modifications.</measure>
    <time_frame>After 24 months from study entry.</time_frame>
    <description>Fasting glucose modifications (diabetic and normo-glycemic patients) and HbA1C modifications (diabetic patients only) during the first 24 months.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of patients with modifications of body mass index during treatment compared to baseline.</measure>
    <time_frame>After 7 years from study entry.</time_frame>
    <description>Modifications of body mass index during treatment compared to baseline.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of patients with modifications of serum lipids during treatment compared to baseline.</measure>
    <time_frame>After 7 years from study entry.</time_frame>
    <description>Modifications of serum lipids during treatment compared to baseline.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Patient reported quality of life.</measure>
    <time_frame>At 3, 6, 9, 12, 18, 24 months from study entry.</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of adverse events.</measure>
    <time_frame>At 3, 6, 9, 12, 18, 24 months from study entry.</time_frame>
  </secondary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Anticipated">133</enrollment>
  <condition>Chronic Myeloid Leukemia</condition>
  <arm_group>
    <arm_group_label>CML patients</arm_group_label>
  </arm_group>
  <intervention>
    <intervention_type>Behavioral</intervention_type>
    <intervention_name>Dasatinib discontinuation</intervention_name>
    <description>Treatment decision is at the discretion of the investigator and must not be made on the basis of this observational study. Patients should have their treatment initiated in accordance with the summary of product characteristics.</description>
    <arm_group_label>CML patients</arm_group_label>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        This is a multicentre, observational, prospective study of newly diagnosed chronic phase
        CML patients treated frontline with Dasatinib 100 mg QD.
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Cytogenetic and/or molecular confirmed diagnosis of Ph+ and/or BCR-ABL+ CML; Age 18
             years;

          -  Early chronic phase, less than 6 months from diagnosis. Prior treatment with
             Hydroxyurea or Anagrelide is allowed;

          -  Signed written informed consent according to ICH/EU/GCP and national local laws prior
             to any study procedures.

        Exclusion Criteria:

          -  Prior treatment with any protein tyrosin-kinase inhibitor (TKI) or interferon;

          -  Recommendations and precautions before allocating a new CML case to dasatinib are
             fully described in the prescribing information.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Michele Baccarani, Pr.</last_name>
    <role>Study Chair</role>
    <affiliation>Orsola Malpighi, Bologna</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Paola Fazi, Dr.</last_name>
    <email>p.fazi@gimema.it</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Enrico Crea</last_name>
    <email>e.crea@gimema.it</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Centro Oncologico Basilicata</name>
      <address>
        <city>Rionero in Vulture</city>
        <state>Potenza</state>
        <country>Italy</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Pellegrino Musto, MD, PhD</last_name>
    </contact>
    <investigator>
      <last_name>Pellegrino MUSTO, Pr.</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Giuseppe Pietrantuono, Dr.</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>S.O.C. di Ematologia - Azienda Ospedaliera - SS. Antonio e Biagio e Cesare Arrigo</name>
      <address>
        <city>Alessandria</city>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Massimo Pini</last_name>
    </contact>
    <investigator>
      <last_name>Gioacchino Catania</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Massimo Pini</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Azienda Ospedaliera - Nuovo Ospedale &quot;Torrette&quot;</name>
      <address>
        <city>Ancona</city>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Serena Rupoli</last_name>
    </contact>
    <investigator>
      <last_name>Serena Rupoli</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Anna Rita</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>U.O.C. Ematologia e Terapia Cellulare - Ospedale &quot;C. e G. Mazzoni&quot; di Ascoli Piceno</name>
      <address>
        <city>Ascoli Piceno</city>
        <country>Italy</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Catia Bigazzi</last_name>
    </contact>
    <investigator>
      <last_name>Catia Bigazzi</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Az.Ospedaliera S.G.Moscati</name>
      <address>
        <city>Avellino</city>
        <country>Italy</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Fausto Palmieri</last_name>
    </contact>
    <investigator>
      <last_name>Fausto Palmieri</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Antonio Volpe</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>UO Ematologia con trapianto-Università degli Studi di Bari Aldo Moro</name>
      <address>
        <city>Bari</city>
        <country>Italy</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Giorina Specchia</last_name>
    </contact>
    <investigator>
      <last_name>Giorgina Specchia</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Antonella Russo</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Azienda Ospedaliera Di Bologna Policlinico S. Orsola - Malpighi</name>
      <address>
        <city>Bologna</city>
        <zip>40138</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Gianantonio Rosti, Dr.</last_name>
      <email>gianantonio.rosti@unibo.it</email>
    </contact>
    <investigator>
      <last_name>Gianantonio Rosti, Dr.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>U.O.C. di Onco-Ematologia - Centro di Ricerca e Formazione ad Alta tecnologia nelle Scienze Biomediche</name>
      <address>
        <city>Campobasso</city>
        <country>Italy</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Sergio Storti</last_name>
    </contact>
    <investigator>
      <last_name>Sergio Storti</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Cristiana Gasbarrino, Dr.</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>US Dipartimentale - Centro per le malattie del sangue - Ospedale Civile - S.Giacomo</name>
      <address>
        <city>Castelfranco Veneto</city>
        <country>Italy</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Giuseppe Tagariello, Dr.</last_name>
    </contact>
    <investigator>
      <last_name>Giuseppe Tagariello, Dr.</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Roberto Sartori, Dr.</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Università di Catania - Cattedra di Ematologia - Ospedale &quot;Ferrarotto&quot;</name>
      <address>
        <city>Catania</city>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Fabio Stagno</last_name>
    </contact>
    <investigator>
      <last_name>Fabio Stagno</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Azienda Ospedaliero Universitaria Arcispedale Sant'Anna Dipartimento di Scienze Mediche Sezione di Ematologia e Fisiopatologia dell'Emostasi</name>
      <address>
        <city>Ferrara</city>
        <country>Italy</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Antonio Cuneo</last_name>
    </contact>
    <investigator>
      <last_name>Antonio Cuneo</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Francesco Cavazzini</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Azienda Ospedaliera di Firenze</name>
      <address>
        <city>Firenze</city>
        <zip>50011</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Alberto BOSI, Pr.</last_name>
    </contact>
    <investigator>
      <last_name>Alberto BOSI, Pr.</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Antonella Gozzini, Dr.</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Centro Aziendale di Ematologia ASL N. 6</name>
      <address>
        <city>Livorno</city>
        <country>Italy</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Enrico CAPOCHIANI</last_name>
      <phone>0586223111</phone>
      <email>e.capochiani@nord.usl6.toscana.it</email>
    </contact>
    <investigator>
      <last_name>Enrico Capochiani, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Azienda Ospedaliera Universitaria - Policlinico G. Martino Dipartimento di Medicina Interna - U.O. Messina</name>
      <address>
        <city>Messina</city>
        <country>Italy</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Caterina Musolino</last_name>
    </contact>
    <investigator>
      <last_name>Caterina Musolino</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Alessandro Allegra</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Divisione di Ematologia - Azienda Ospedaliera Ospedali Riuniti &quot;Papardo Piemonte&quot;</name>
      <address>
        <city>Messina</city>
        <country>Italy</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Maura Brugiatelli</last_name>
    </contact>
    <investigator>
      <last_name>Maura Brugiatelli</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Laura Nocilli</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico UOC Oncoematologia- Padiglione Marcora 2° piano</name>
      <address>
        <city>Milano</city>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Alessandra Iurlo</last_name>
    </contact>
    <investigator>
      <last_name>Alessandra Iurlo</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Ospedale San Gennaro - ASL Napoli 1</name>
      <address>
        <city>Napoli</city>
        <country>Italy</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Lucia Mastrullo</last_name>
    </contact>
    <investigator>
      <last_name>Lucia Mastrullo</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Maria Rosaria</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>zienda Ospedaliera Universitaria - Università degli Studi di Napoli &quot;Federico II&quot; - Facoltà di Medicina e Chirurgia</name>
      <address>
        <city>Napoli</city>
        <country>Italy</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Fabrizio Pane</last_name>
    </contact>
    <investigator>
      <last_name>Fabrizio Pane</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Luigia Luciano</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Dip. di Scienze Cliniche e Biologiche - Ospedale S. Luigi Gonzaga-Medicina Interna 2</name>
      <address>
        <city>Orbassano</city>
        <country>Italy</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Giovanna Rege</last_name>
    </contact>
    <investigator>
      <last_name>Giovanna Rege</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Carmen Fava</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>La Maddalena Casa di Cura di Alta Specialità Dipartimento Oncologico di III Livello</name>
      <address>
        <city>Palermo</city>
        <country>Italy</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Maurizio Musso</last_name>
    </contact>
    <investigator>
      <last_name>Maurizio Musso</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Ferdinando Porretto</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>zienda Ospedaliera Universitaria - Università degli Studi di Napoli &quot;Federico II&quot; - Facoltà di Medicina e Chirurgia</name>
      <address>
        <city>Palermo</city>
        <country>Italy</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Diamante Turri</last_name>
    </contact>
    <investigator>
      <last_name>Diamante Turri</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Cattedra di Ematologia CTMO Università degli Studi di Parma</name>
      <address>
        <city>Parma</city>
        <country>Italy</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Monica Crugnola</last_name>
    </contact>
    <investigator>
      <last_name>Monica Crugnola</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Franco Aversa</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>U.O. Ematologia Clinica - Azienda USL di Pescara</name>
      <address>
        <city>Pescara</city>
        <country>Italy</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Roberto Di Lorenzo</last_name>
    </contact>
    <investigator>
      <last_name>Roberto Di Lorenzo</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Giuseppina Ricciuti</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Unità Operativa Ematologia e Centro Trapianti - Dipartimento di Oncologia ed Ematologia - AUSL Ospedale di Piacenza</name>
      <address>
        <city>Piacenza</city>
        <country>Italy</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Daniele Vallisa, Dr.</last_name>
    </contact>
    <investigator>
      <last_name>Daniele Vallisa, Dr.</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Elena Trabacchi, Dr.</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Dipartimento Emato-Oncologia A.O.&quot;Bianchi-Melacrino-Morelli&quot;</name>
      <address>
        <city>Reggio Calabria</city>
        <country>Italy</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Francesco Nobile</last_name>
    </contact>
    <investigator>
      <last_name>Francesco Nobile</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Bruno Martino</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Unità Operativa Complessa di Ematologia - Arcispedale S. Maria Nuova</name>
      <address>
        <city>Reggio Emilia</city>
        <country>Italy</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Paolo Avanzini</last_name>
    </contact>
    <investigator>
      <last_name>Paolo Avanzini</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Isabella Capodanno</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Az. Ospedaliera &quot;Sant' Andrea&quot;-Università la Sapienza Seconda Facoltà di Medicina e Chirurgia</name>
      <address>
        <city>Roma</city>
        <country>Italy</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Enrico Montefusco</last_name>
    </contact>
    <investigator>
      <last_name>Enrico Montefusco</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Raffaele Porrini</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Complesso Ospedaliero S. Giovanni Addolorata</name>
      <address>
        <city>Roma</city>
        <country>Italy</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Michele Cedrone, Dr.</last_name>
    </contact>
    <investigator>
      <last_name>Barbara Anaclerico, Dr.</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Michele Cedrone, Dr.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Padiglione Cesalpino - I piano - Divisione di Ematologia - Ospedale S. Camillo</name>
      <address>
        <city>Roma</city>
        <country>Italy</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Leonardo Pacilli</last_name>
    </contact>
    <investigator>
      <last_name>Leonardo Pacilli</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>S.C. di Ematologia e Trapianti - I.F.O. Istituto Nazionale Tumori Regina Elena</name>
      <address>
        <city>Roma</city>
        <country>Italy</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Atelda Romano, Dr.</last_name>
    </contact>
    <investigator>
      <last_name>Atelda Romano, Dr.</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Laura Nocilli, Dr.</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>U.O.C. Ematologia - Ospedale S.Eugenio</name>
      <address>
        <city>Roma</city>
        <country>Italy</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Elisabetta Abruzzese</last_name>
    </contact>
    <investigator>
      <last_name>Elisabetta Abruzzese</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Monika Trawinska</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Università Cattolica del Sacro Cuore - Policlinico A. Gemelli</name>
      <address>
        <city>Roma</city>
        <country>Italy</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Simona Sica</last_name>
    </contact>
    <investigator>
      <last_name>Simona Sica</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Federica Sorà</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Rotondo Istituto di Ematologia - IRCCS Ospedale Casa Sollievo della Sofferenza</name>
      <address>
        <city>San Giovanni Rotondo</city>
        <country>Italy</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Nicola Cascavilla</last_name>
    </contact>
    <investigator>
      <last_name>Nicola Cascavilla</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Antonietta Pia</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>U.O.C. Ematologia e Trapianti - A.O. Senese - Policlinico &quot; Le Scotte&quot;</name>
      <address>
        <city>Siena</city>
        <country>Italy</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Monica Bocchia</last_name>
    </contact>
    <investigator>
      <last_name>Monica Bocchia</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Lara Aprile</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Dipartimento di Oncologia ed Ematologia S.C. Ematologia 2 A.O. Città della Salute e della Scienza di Torino San Giovanni Battista</name>
      <address>
        <city>Torino</city>
        <country>Italy</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Patrizia Pregno</last_name>
    </contact>
    <investigator>
      <last_name>Patrizia Pregno</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Paola Riccomagno</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Clinica Ematologica - Policlinico Universitario</name>
      <address>
        <city>Udine</city>
        <country>Italy</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Mario Tiribelli</last_name>
    </contact>
    <investigator>
      <last_name>Mario Tiribelli</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Luciana Marin</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Università degli Studi di Verona - A. O. - Istituti Ospitalieri di Verona- Div. di Ematologia - Policlinico G.B. Rossi</name>
      <address>
        <city>Verona</city>
        <country>Italy</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Giovanni Pizzolo</last_name>
    </contact>
    <investigator>
      <last_name>Giovanni Pizzolo</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Massimiliano Bonifacio</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Italy</country>
  </location_countries>
  <link>
    <url>http://www.gimema.it</url>
    <description>GIMEMA Foundation</description>
  </link>
  <verification_date>February 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>January 3, 2013</study_first_submitted>
  <study_first_submitted_qc>January 4, 2013</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 7, 2013</study_first_posted>
  <last_update_submitted>February 20, 2018</last_update_submitted>
  <last_update_submitted_qc>February 20, 2018</last_update_submitted_qc>
  <last_update_posted type="Estimate">February 21, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Chronic Myeloid Leukemia</keyword>
  <keyword>Early phase</keyword>
  <keyword>CML</keyword>
  <keyword>Dasatinib</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Leukemia</mesh_term>
    <mesh_term>Leukemia, Myeloid</mesh_term>
    <mesh_term>Leukemia, Myelogenous, Chronic, BCR-ABL Positive</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Dasatinib</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

